Disinfection of water in swimming pools by combined action of UV-light and ozone

Disinfection of water in swimming pools by combined action of UV-light and ozone / 258st American Chemical Society National Meeting and Exposition «Division of Environmental Chemistry», august 25-29, 2019, San Diego, CA. ENVR 394.P.5

Dietary fiber is a reliable and apparent element of treatment for patients with type 2 diabetes mellitus and cardiovascular diseases: an easy solution to a complicated problem

Cardiovascular diseases are a frequent comorbid condition in patients with type 2 diabetes mellitus (t2DM). This problem tends to remain acute because of the progression of t2DM, which increases the chances of cardiovascular events. Medicine today has a range of innovative hypoglycemic drugs, which proved their safety and effectiveness towards diseases of cardiovascular system. However, high cardiovascular mortality demonstrates that the medication is not enough effective. Partly lack of success may be explained by not enough work with unmodified risk factors, such as physical activity, smoking and excessive and wrong nutrition. Studies about dietary fiber (DF) let us discuss their including in the dietary plan of patients with t2DM and cardiovascular diseases. One of the promising DF types is Cyamopsis tetragonoloba extract. It showed its effectiveness concerning carbohydrate metabolism and lipid profile, improving, metabolic features of t2DM patients and lowering the risks of cardiovascular events. What is more, the advantage of Cyamopsis tetragonoloba extract is easy to use and has no side effects

DEVELOPING A MODEL OF COOKING GRAIN BATCH

Summary. By batch cooking of grain accumulated considerable experimental and production material. However, the theory of this process has not been developed to the desired extent. It is shown that the mathematical modeling of the process of cooking the grain batch can be used as a basis for non-stationary diffusion equation and its numerical solution based on the grid method. It is shown that in addition to non-stationary diffusion process by using the grid method can take into account the temperature processes and the theory of swelling of the starch granules. The values of the activation energy of diffusion bound moisture in grains and the pre-exponential value were determined. To describe the swelling of the starch granules used solutions sufficiently numerous studies, and the selected model based on chemical reaction kinetics of the second order. Elaboration of the model of cooking done on experimental data for wheat grits, and concluded the need to address the gap of the starch granules during swelling and separation of layers of material adjacent to the liquid phase during the entire process until the complete cooking of cereal grits. An enlarged under a microscope photos edge dry and tenderized particles showing swelling of the starch granules and the isolation of the outer layer of the particle. Simultaneously taken into account in the model dynamics of temperature changes during heating and mixing the grain of cooking. The simulation results are identified according to a pilot study of cooking barley grits. Found that the developed model accurately describes the results of the pilot study. It is shown that the mathematical model based on the non-stationary diffusion equation, excluding the effects of temperature and swelling of the starch granulestheory gives too high of cooking time

Dielectric and magnetic responses in nanocrystalline BaTiO3

This work was supported by Russian Foundation for Basic Research (Research Project No.18-52-00039 Bel_a)

Нестероидные противовоспалительные препараты:возможности снижения интенсивности боли в спине у больных остеопорозом

Objective: to evaluate the efficiency and tolerability of a 10-day course of therapy with different doses of meloxicam in patients with osteoporosis and back pain. Subjects and methods. The study covered 60 women (mean age 70±7 years), who were randomized to 3 groups: those who received meloxicam in doses of 15 and 7,5 mg and controls. Results. During 10-day therapy, there was a significant reduction in the intensity of back pain when meloxicam was given in doses of both 7,5 mg and 15 mg/day (p < 0,001) as compared with the baseline level and in the control group (p < 0,05). At the same time, the pain syndrome became insignificantly lower in the control group following 10 days (p > 0,05). In the first 2 groups, movement restriction significantly reduced, as well as physical activity increased and health improved, as rated by the Oswestry and EQ-5D questionnaires. Improvement was recorded in 27 (67,5%) patients, a satisfactory effect was seen in 10 (25%), there was no effect in 3 (7,5%) women. Conclusion. The treatment was generally well tolerated.Цель исследования- оценить эффективность и переносимость 10-дневного курса лечения различными дозами мелоксикама у больных с остеопорозом и болью в спине. Материал и методы. В исследование включены 60 женщин (средний возраст 70±7 лет), которые случайно были разделены на 3 группы - получавшие соответственно 15 и 7,5мг мелоксикама и контроль. Результаты исследования. На фоне 10-дневной терапии отмечалось достоверное снижение интенсивности боли в спине при назначении мелоксикама в дозе как 7,5, так и 15 мг/сут (p<0,001) по сравнению с уровнем боли при включении в исследование и в контрольной группе (p<0,05). При этом в контрольной группе через 10 дней болевой синдром уменьшился незначительно (p>0,05). У пациенток первых 2 групп достоверно снизилось ограничение подвижности, а также повысилась физическая активность, улучшилось состояние здоровья, оцененное по вопросникам Освестри и EQ-5D. Улучшение состояния зафиксировано у 27 (67,5%) больных, удовлетворительный эффект - у 10 (25%), а отсутствие эффекта - у 3 (7,5%). Заключение. В целом переносимость лечения была хорошей

The Electron Calorimeter (ECAL) Long Duration Balloon Experiment

Accurate measurements of the cosmic ray electron energy spectrum in the energy region 50 GeV to greater than 1 TeV may reveal structure caused by the annihilation of exotic dark matter particles and/or individual cosmic ray sources. Here we describe a new long duration balloon (LDB) experiment, ECAL, optimized to directly measure cosmic ray electrons up to several TeV. ECAL includes a double layer silicon matrix, a scintillating optical fiber track imager, a neutron detector and a fully active calorimeter to identify more than 90% of the incident electrons with an energy resolution of about 1.7% while misidentifying only 1 in 200,000 protons and 0.8% of secondary gamma rays as electrons. Two ECAL flights in Antarctica are planned for a total exposure of 50 days with the first flight anticipate for December 2009

Приверженность лечению деносумабом, его эффективность и безопасность в клинической практике у женщин с постменопаузальным остеопорозом

Adherence to treatment with antiosteoporotic drugs is one of the most important factors contributing to their efficacy during longterm therapy. The adherence is assessed by two main lines: firstly, how long a drug is taken and, secondly, whether its dosage regimen is adhered.Subjects and methods. The paper gives the data of a 12-month prospective follow-up study of 40 women with postmenopausal osteoporosis (OP) who initiated treatment with the biological agent denosumab.Results and discussion. After the 12-month follow-up, the significant bone mineral density increase was 4.9% in the lumbar spine, 3.2% in the femoral neck, and 3.0% in the total hip. The previous administration of other antiosteoporotic drugs did not lower the efficiency of denosumab therapy. There were no cases of osteoporotic fractures during 1-year follow-up. 95% of the patients received two denosumab injections (an annual cycle); moreover, 90% of the women were noted to adhere to the dosage regimen. Age, marital status, level of education, time taken to reach the clinic, parental femoral fractures, a history of fractures, duration of OP, and previous therapy had no impact on treatment adherence during 12 months.Conclusion. The one-year prospective follow-up study of the outpatients demonstrated that denosumab was an effective and safe agent for the treatment of patients with postmenopausal OP and its dosage regimen implying its rare subcutaneous administration (twice yearly) ensured the high patient adherence to therapy.Приверженность лечению антиостеопоротическими препаратами является одним из важных факторов, вносящих вклад в их эффективность при длительном лечении. Приверженность оценивается по двум основным направлениям: во-первых, как длительно принимается препарат, и, во-вторых, соблюдается ли режим дозирования.Пациенты и методы. В статье представлены данные 12-месячного проспективного наблюдения за 40 женщинами с постменопаузальным остеопорозом (ОП), начавших лечение генно-инженерным препаратом деносумаб.Результаты и обсуждение. Достоверный прирост минеральной плотности кости через 12 мес наблюдения составил 4,97% в поясничном отделе позвоночника, 3,2% – в шейке бедра, 3,0% – в общем показателе бедра. Предшествующий прием других противоостеопоротических препаратов не снижал эффективности лечения деносумабом. Не было случаев остеопоротических переломов за год наблюдения. Две инъекции деносумаба (годовой курс) получили 95% пациенток, при этом соблюдение режима дозирования было отмечено у 90% женщин. На приверженность лечению в течение 12 мес не оказывали влияния возраст, семейное положение, уровень образования, время на дорогу до клиники, наличие переломов бедра у родителей, переломы в анамнезе, длительность ОП и предшествующая терапия.Заключение. Проведенное одногодичное проспективное наблюдение, выполненное в условиях амбулаторной практики, показало, что деносумаб – эффективное и безопасное средство для лечения больных с постменопаузальным ОП, а режим дозирования, разумевающий редкое его введение (2 раза в год подкожно), обеспечил высокую приверженность терапии

Efficacy and safety of diacerein in patients with knee osteoarthritis

Diacerein (D) belongs to a class of symptomatic slow-acting agents, has an original mechanism of action, and is widely used as a diseasemodifying antirheumatic drug to treat osteoarthritis (OA) in Russia and many countries of the world. The ability of the drug to affect the main symptoms and progression of OA has been shown in a number of well-organized clinical trials.Objective: to evaluate the efficacy and safety of D in patients with knee OA.Patients and methods. An open-label trial evaluating the efficacy and safety of D (diaflex) in patients with knee OA was conducted in accordance with the multicenter program «Osteoarthrosis: Assessment of Progression in Real Clinical Practice». The trial included 80 patients of both sexes with Stage II–III knee OA; mean age, 60.8±6.8 years (47–75 years); mean body mass index, 31.8±5.9 kg/m2; disease duration, 10.3±5.7 years (2–30 years). The duration of the trial was 9 months (6 months of therapy and 3 months of follow-up).Results. There was a statistically significant reduction in visual analog scale pain on walking just 1 month after therapy initiation (57.1±9.7 and 44.7±13.9 mm; p<0.0001) and a further significant improvement throughout the 6-month therapy. Pain did not increase after the drug was discontinued (the follow-up period was 3 months). The same pattern was observed in the assessment of the WOMAC index (pain during early therapy, 243.8±73.9; pain at the end of therapy, 137.5±78.9; stiffness, 97.8±41.1 and 57.7±38.6; functional failure, 875.8±250.4 and 525±305.7 respectively; p<0.0001). Statistically significantly improved quality of life indicators measured by EQ-5D were noted throughout the follow-up period: 0.43±0.23 at the beginning of therapy, 0.61±0.14 at its end, and 0.63±0.11 at 3 months following treatment completion (p<0.0001). By the time of therapy completion, 71.3% of the patients completely refused to take nonsteroidal anti-inflammatory drugs (NSAIDs). Both the patient and the physician evaluated the efficiency of treatment identically. By the end of therapy, 87.5% of the patients were observed to have improvement. Adverse reactions (ARs) were recorded in 10 (12.5%) patients and mainly associated with more frequent stools; ARs were not a cause of treatment interruptions or protocol deviations.Conclusion. Diaflex has a good symptomatic and anti-inflammatory effect: the therapy statistically significantly reduces pain, stiffness, and the need for NSAIDs and improves quality of life and joint function. The drug has a good safety profile and after-effects, which is seen at least 3 months after therapy discontinuation

Measurement of inclusive D*+- and associated dijet cross sections in photoproduction at HERA

Inclusive photoproduction of D*+- mesons has been measured for photon-proton centre-of-mass energies in the range 130 < W < 280 GeV and a photon virtuality Q^2 < 1 GeV^2. The data sample used corresponds to an integrated luminosity of 37 pb^-1. Total and differential cross sections as functions of the D* transverse momentum and pseudorapidity are presented in restricted kinematical regions and the data are compared with next-to-leading order (NLO) perturbative QCD calculations using the "massive charm" and "massless charm" schemes. The measured cross sections are generally above the NLO calculations, in particular in the forward (proton) direction. The large data sample also allows the study of dijet production associated with charm. A significant resolved as well as a direct photon component contribute to the cross section. Leading order QCD Monte Carlo calculations indicate that the resolved contribution arises from a significant charm component in the photon. A massive charm NLO parton level calculation yields lower cross sections compared to the measured results in a kinematic region where the resolved photon contribution is significant.Comment: 32 pages including 6 figure

Measurement of Jet Shapes in Photoproduction at HERA

The shape of jets produced in quasi-real photon-proton collisions at centre-of-mass energies in the range $134-277$ GeV has been measured using the hadronic energy flow. The measurement was done with the ZEUS detector at HERA. Jets are identified using a cone algorithm in the $\eta - \phi$ plane with a cone radius of one unit. Measured jet shapes both in inclusive jet and dijet production with transverse energies $E^{jet}_T>14$ GeV are presented. The jet shape broadens as the jet pseudorapidity ($\eta^{jet}$) increases and narrows as $E^{jet}_T$ increases. In dijet photoproduction, the jet shapes have been measured separately for samples dominated by resolved and by direct processes. Leading-logarithm parton-shower Monte Carlo calculations of resolved and direct processes describe well the measured jet shapes except for the inclusive production of jets with high $\eta^{jet}$ and low $E^{jet}_T$. The observed broadening of the jet shape as $\eta^{jet}$ increases is consistent with the predicted increase in the fraction of final state gluon jets.Comment: 29 pages including 9 figure